目的 探讨血清抗着丝粒蛋白F抗体（anti-centromere protein F antibody，anti-CENPF）在乳腺癌中的临床价值。 方法 收集100例初诊乳腺癌（breast cancer，BC）患者、40例乳腺良性疾病（non breast cancer，non-BC）患者和40名健康体检者（healthy control，HC）血清，采用酶联免疫吸附试验检测血清中的anti-CENPF水平，同时化学发光法测定血清糖类抗原153（carbohydrate antigen 153，CA153）的水平。 结果 BC组血清anti-CENPF水平高于non-BC组和HC组，差异有统计学意义（P<0.05）。anti-CENPF和CA153诊断乳腺癌中的曲线下面积（area under the curve，AUC）分别为0.714和0.672，两者联合检测的AUC为0.739。有淋巴结转移、远处转移或者人表皮生长因子受体2（human epidermal growth factor receptor-2，HER-2）阴性的乳腺癌患者血清anti-CENPF浓度明显升高（P<0.05）。不同肿瘤大小、临床分期、分子分型乳腺癌患者血清anti-CENPF水平比较，差异有统计学意义（P<0.05）。组间比较显示Ⅳ期和Ⅲ期血清anti-CENPF浓度高于Ⅰ期和Ⅱ期，HER-2过表达型、Luminal B型血清anti-CENPF水平低于三阴性乳腺癌（triple negative breast cancer，TNBC）患者。雌激素受体（receptors estrogen，ER）阳性的乳腺癌患者中，HER-2阴性组的anti-CENPF浓度高于HER-2阳性组，差异有统计学意义（P=0.026）。 结论 血清anti-CENPF在乳腺癌的诊断、临床分期及分子分型中发挥了重要作用，其水平可能与乳腺癌预后呈负相关，有望成为乳腺癌潜在的疾病标志物。

Objective To investigate the clinical value of serum anti-centromere protein F antibody（anti-CENPF） in breast cancer. Methods Serum samples were collected from 100 breast cancer patients（BC group），40 patients with benign breast disease（non-BC group），and 40 healthy controls（HC group）. Enzyme-linked immunosorbent assay was used to measure the serum level of anti-CENPF，and chemiluminescence was used to measure the serum level of carbohydrate antigen 153（CA153）. Results The BC group had a significantly higher serum level of anti-CENPF than the non-BC group and the HC group（P<0.05）. The receiver operating characteristic（ROC） curve analysis showed that anti-CENPF and CA153 had an area under the ROC curve（AUC） of 0.714 and 0.672，respectively，in the diagnosis of breast cancer，and the combination of anti-CENPF and CA153 had an AUC of 0.739. There was a significant increase in the concentration of serum anti-CENPF in breast cancer patients with lymph node metastasis，distant metastasis，or negative human epidermal growth factor receptor 2（HER-2）（P<0.05）. There was a significant difference in the serum level of anti-CENPF between breast cancer patients with different tumor sizes，clinical stages，and molecular types（P<0.05）. Comparison between groups showed that patients with stage Ⅲ/Ⅳ breast cancer had a significantly higher serum level of anti-CENPF than those with stage Ⅰ/Ⅱ breast cancer，and patients with HER-2 overexpression or Luminal B type breast cancer had a significantly lower serum level of anti-CENPF than those with triple negative breast cancer. Among patients with estrogen receptor-positive breast cancer，the HER-2 negative group had a significantly higher concentration of anti-CENPF than the HER-2 positive group（P=0.026）. Conclusion Serum anti-CENPF plays an important role in the diagnosis，clinical staging，and molecular typing of breast cancer，and the level of anti-CENPF may be negatively correlated with the prognosis of breast cancer. Therefore，it is expected to become a potential disease marker for breast cancer.